Why Does the Immune System Attack the Eyes?

The eyes occupy a paradoxical position in the body’s defense network: they are among the most immunologically protected organs, yet they remain vulnerable to a surprising range of autoimmune attacks. The eye maintains what researchers call “immune privilege,” a set of active mechanisms that suppress inflammatory responses inside the globe to protect the delicate tissues that make vision possible. When those mechanisms fail, or when the immune system is activated so strongly that it overrides them, the result can be anything from mild redness to permanent blindness. The reasons range from mistaken identity at the molecular level to collateral damage from diseases that start in entirely different organs.

The Eye’s Built-In Immune Shield

To understand why the immune system sometimes attacks the eyes, you first need to appreciate how hard the eye works to prevent that from happening. The eye is not simply hidden from immune cells. It actively suppresses them. The retina, for instance, is sealed behind two physical barriers: an inner barrier made of tightly joined blood vessel cells supported by surrounding glia, and an outer barrier formed by a layer of pigmented cells separating the retina from the blood-rich choroid beneath it. These barriers keep most immune cells and large molecules out of the neural retina entirely.¹

Physical walls are only part of the story. The fluid inside the eye is loaded with immunosuppressive molecules, including TGF-β2 and α-MSH, that actively restrain immune cells and push them toward less inflammatory behavior.¹ The eye also runs a process called anterior chamber-associated immune deviation, or ACAID, which is a systemic tolerance mechanism. When foreign material enters the front chamber of the eye, the eye sends signals that suppress the body’s aggressive immune response to that material throughout the entire body, not just locally.² This protects the eye from the collateral damage that a full immune assault would cause. The evolutionary logic is straightforward: the structures that allow precise vision are extremely fragile, and even a well-intentioned immune response can destroy them.³

These defenses are impressive, but they are not absolute. When the barriers break down, when the immune system is triggered by signals strong enough to override the eye’s suppressive environment, or when systemic autoimmune disease generates sustained attacks, the eye becomes a target.

Molecular Mimicry and Mistaken Identity

One of the most well-studied routes by which the immune system ends up attacking the eye is molecular mimicry. The idea is simple in concept: a protein from a bacterium, virus, or other foreign source looks similar enough to a protein naturally present in the eye that immune cells trained to fight the invader end up attacking eye tissue instead. T cells activated by these look-alike proteins outside the eye can cross the blood-retina barrier and, once inside, become reactivated by the retinal proteins they cross-react with. That triggers a cascade of inflammation called uveitis.⁴

Researchers have identified specific examples. A peptide sequence from the HLA-B27 molecule, a cell-surface protein involved in presenting bits of foreign material to the immune system, shares five amino acids with a retinal protein called S-antigen. That overlap could be enough to cause immune cells to mistake retinal tissue for a foreign threat.⁵ This is particularly relevant because HLA-B27 is one of the strongest genetic risk factors for a common form of eye inflammation, acute anterior uveitis.

Genetic Risk and HLA-B27

The link between the HLA-B27 gene and eye inflammation is one of the most robust connections in all of autoimmune medicine.⁶ People who carry this gene variant are at dramatically increased risk of developing acute anterior uveitis, the most common type of uveitis, which causes sudden pain, redness, and light sensitivity in one eye. The same gene is also linked to a cluster of related inflammatory conditions including ankylosing spondylitis, inflammatory bowel disease, and psoriatic arthritis. Large genetic studies have confirmed that anterior uveitis is a polygenic disease with significant overlap in risk genes with these other conditions.⁷

Carrying HLA-B27 does not guarantee you will develop uveitis. Most people with the gene variant never do. But if you have HLA-B27 and also have one of the associated inflammatory conditions, the risk rises substantially. Your ophthalmologist will often ask about joint pain, back stiffness, or digestive issues specifically because these conditions travel together. The reverse is also true: if you present with anterior uveitis, your doctor may test for HLA-B27 and screen for related systemic disease.

When Trauma Breaks the Barrier

Physical injury to the eye can expose previously hidden ocular proteins to the immune system, sometimes with devastating consequences. The most dramatic example is sympathetic ophthalmia, a condition in which penetrating trauma or surgery to one eye triggers an immune attack not just on the injured eye but on the uninjured eye as well. This bilateral inflammation typically appears days to months after the original injury.⁸

The working explanation is that the trauma exposes retinal and uveal antigens that the immune system has never encountered before because they were sealed behind the blood-retina barrier. Once the immune system mounts a response to those antigens, the immune cells can find and attack the same antigens in the other eye, which was never injured at all. The condition is rare, but when it occurs, it can cause blindness in both eyes if not treated aggressively with immunosuppression.⁹ Sympathetic ophthalmia is a sobering illustration of what happens when immune privilege fails suddenly and completely.

Graves’ Eye Disease and Shared Autoantigens

The immune system’s attack on the eye does not always involve the structures inside the globe. In Graves’ disease, the most common cause of hyperthyroidism, antibodies directed against the thyroid-stimulating hormone receptor (TSHR) cause the thyroid gland to overproduce hormones. But TSHR is also present on cells called orbital fibroblasts, the connective tissue cells that surround and cushion the eye in its socket. In people with Graves’ ophthalmopathy, the same antibodies attack these orbital cells, causing them to swell and produce excess tissue. The result is bulging eyes, double vision, pain, and in severe cases, compression of the optic nerve.¹⁰

Research has shown that orbital fibroblasts from patients with Graves’ eye disease express higher levels of both TSHR and the receptor for insulin-like growth factor (IGF-1R) compared to healthy controls. IGF-1 appears to amplify the effects of the autoimmune antibodies on orbital tissue, making the inflammatory response worse.¹¹ This is a case where the eye is collateral damage: the immune system was never “aiming” at the eye specifically. It was targeting TSHR wherever it found it, and the orbit happened to be expressing that target protein.

Sjögren’s Syndrome and the Tear Glands

Sjögren’s syndrome offers yet another mechanism of immune attack. In this chronic autoimmune condition, lymphocytes infiltrate and progressively destroy the body’s moisture-producing glands, especially the lacrimal (tear) glands and salivary glands. The hallmark ocular manifestation is keratoconjunctivitis sicca, a severe form of dry eye caused by insufficient tear production.¹² Unlike uveitis, which is inflammation inside the eye, Sjögren’s attacks the support system around the eye. Without adequate tears, the corneal surface dries out, becomes inflamed, and can develop ulcers and scarring.

Primary Sjögren’s syndrome mainly affects exocrine glands, and its inflammatory process is driven by autoimmunity against the glandular tissue itself.¹³ The eye is caught up in this because the lacrimal gland is precisely the type of tissue the disease targets. For many patients, dry eye is actually the first symptom that leads to diagnosis of the underlying autoimmune condition.

The Complement System and Age-Related Macular Degeneration

Not every immune-mediated eye disease fits the classic autoimmune pattern of antibodies or T cells attacking healthy tissue. Age-related macular degeneration, or AMD, the leading cause of vision loss in older adults, has a strong immune component driven by the complement system, an ancient arm of innate immunity that normally helps clear debris and tag pathogens. Complement Factor H (CFH) is a protein that keeps the complement system in check, preventing it from damaging the body’s own cells. Genetic variants in the CFH gene represent the strongest known genetic risk factors for AMD.¹⁴

When CFH does not function properly, the complement system runs unchecked in the retina, contributing to chronic low-grade inflammation. Research in mouse models has revealed a specific mechanism: CFH binds to a receptor on immune cells called CD11b, and this binding blocks the normal process by which these cells are cleared from the subretinal space. The AMD-associated variant of CFH markedly increases this blocking effect, causing immune cells to accumulate where they do not belong.¹⁵ The drusen deposits that characterize AMD contain inflammatory mediators, further supporting the idea that immune-mediated processes are major drivers of the disease.¹⁶

Microglia, the resident immune cells of the retina, also play a role. Under normal conditions they perform housekeeping functions. But in chronic retinal degenerative conditions, microglia become pathologically activated and release excessive amounts of inflammatory mediators that promote tissue damage.¹⁷ In the aging retina, these changes are accompanied by microglial migration into the subretinal space and breakdown of the blood-retinal barrier, creating a state of chronic “para-inflammation” that can tip toward frank disease.¹⁸

The Gut Connection

One of the more surprising areas of research involves the gut microbiome. A growing body of evidence links disturbances in gut bacteria to the development of uveitis. Researchers have proposed four mechanisms by which gut microbiome changes could drive eye inflammation: molecular mimicry (gut bacteria producing proteins that resemble eye proteins), an imbalance between regulatory and inflammatory T cells, increased permeability of the intestinal lining allowing bacterial products to enter the bloodstream, and the loss of beneficial metabolites produced by healthy gut bacteria.¹⁹

The most compelling animal evidence comes from a mouse model genetically engineered to develop spontaneous uveitis. When these mice were raised germ-free or given broad-spectrum antibiotics that wiped out their gut bacteria, they developed significantly less eye disease. Their intestinal Th17 cells, a type of pro-inflammatory immune cell, were markedly reduced. When germ-free mice were re-exposed to normal gut bacteria by co-housing them with conventional mice, uveitis returned.²⁰ Whether manipulating the human microbiome could prevent or treat uveitis remains to be seen, but the genetic risk factor HLA-B27 itself appears to influence the composition of the gut microbiome, which may be one mechanism through which the gene drives eye inflammation.⁷

Antibodies That Target the Optic Nerve

Neuromyelitis optica spectrum disorder, or NMOSD, is a condition in which the immune system produces antibodies against aquaporin-4, a water channel protein found on astrocytes in the brain and spinal cord. The optic nerve is a frequent target. Attacks cause severe optic neuritis, with rapid vision loss that can be permanent. The discovery that these specific antibodies drive the disease fundamentally changed how neurologists understand and treat NMOSD.²¹

Unlike the inflammatory uveitis discussed above, NMOSD attacks the neural tissue of the optic nerve itself, causing demyelination, the stripping away of the insulating sheath that allows nerve signals to travel efficiently. In a Japanese cohort of 69 patients with anti-aquaporin-4 antibody-positive optic neuritis, the condition was studied to assess clinical characteristics and the effectiveness of ongoing immune-suppressive maintenance therapy.²² The condition tends to relapse, making long-term immunosuppression important for preserving remaining vision.

When Systemic Disease Inflames the Eye

Several multisystem inflammatory diseases routinely involve the eye. Behçet’s syndrome is a condition marked by recurrent mouth sores, genital ulcers, skin lesions, and uveitis. Sarcoidosis, a granulomatous disorder of unknown cause, also commonly causes eye inflammation. The two can be difficult to distinguish because they share so many features, including uveitis, arthritis, skin rashes, and neurologic involvement.²³

In these conditions, the eye is not uniquely targeted. It is one of many organs affected by a body-wide inflammatory process. But because the eye’s delicate structures are so easily damaged by inflammation, ocular involvement often causes disproportionate harm and drives treatment decisions. Anti-TNF-α therapies have shown effectiveness in controlling uveitic macular edema in both Behçet’s syndrome and sarcoidosis patients, though their effectiveness varies between the two conditions.²⁴

Cancer Immunotherapy as an Unexpected Trigger

A growing concern is eye inflammation caused by immune checkpoint inhibitors, a class of cancer drugs that work by releasing the brakes on the immune system so it can attack tumors more effectively. The same mechanism that unleashes the immune system against cancer can also unleash it against the eye. Cases of uveitis following checkpoint inhibitor therapy have been reported with increasing frequency as these drugs become more widely used across different cancer types.²⁵

This makes sense in light of what we know about immune privilege: the eye depends on inhibitory checkpoints and regulatory signals to keep immune cells from causing damage. When those checkpoints are pharmacologically blocked throughout the body, the eye loses a critical layer of protection. For oncologists and ophthalmologists managing these patients, the challenge is balancing the cancer-fighting benefits of the drugs against the risk of permanent vision loss from unchecked ocular inflammation.

How Biologic Therapies Changed Treatment

For decades, treating autoimmune eye disease meant corticosteroids and traditional immunosuppressants, drugs that broadly dampen the immune system with significant side effects. The development of biologic therapies, particularly adalimumab (an anti-TNF-α antibody), marked a shift. In a pivotal randomized trial of patients with active noninfectious uveitis, those receiving adalimumab had roughly double the time to treatment failure compared to placebo, with a hazard ratio of 0.50. Secondary outcomes including inflammation levels and visual acuity were also significantly better in the treatment group.²⁶

Smaller retrospective studies have supported these findings, showing that anti-TNF-α therapy controlled ocular inflammation in the majority of patients within a few months and allowed substantial reductions in steroid doses.²⁷ Reducing steroid dependence matters because long-term steroid use itself causes eye problems, including cataracts and glaucoma, creating a cruel irony in which the treatment for immune-mediated eye disease generates additional eye disease.

Scarring Autoimmunity on the Eye Surface

Some autoimmune conditions attack the eye’s mucosal surfaces rather than its interior. Ocular cicatricial pemphigoid is a blistering disease in which the immune system produces antibodies against beta-4 integrin, a structural protein found in the basement membrane of the conjunctiva (the clear tissue lining the inner eyelids and white of the eye). These antibodies deposit at the base of the conjunctival epithelium, triggering chronic inflammation that leads to progressive scarring, fusion of the eyelids to the eyeball, and eventually blindness if untreated.²⁸ Because beta-4 integrin is also present in skin and other mucous membranes, some patients develop blistering at those sites as well, but the ocular disease is often the most sight-threatening component.

Cellular Fine-Tuning Gone Wrong

At the cellular level, autoimmune uveitis involves a tug-of-war between pro-inflammatory T cell subsets and the regulatory T cells that normally keep them in check. In experimental models of uveitis, mice lacking a receptor for type III interferons develop more severe eye disease, with amplified Th1 and Th17 inflammatory responses, fewer regulatory T cells, and more extensive breakdown of the blood-retinal barrier, including loss of key tight junction proteins.²⁹ Findings like these are helping researchers identify new therapeutic targets. Rather than broadly suppressing the entire immune system, future treatments may be able to selectively restore the regulatory side of the balance, dampening the attack on the eye without leaving the patient vulnerable to infections.

The picture that emerges from all of this research is that the immune system does not attack the eyes for a single reason. The eye sits at the intersection of physical barriers, chemical signals, genetic susceptibility, microbial influences, and systemic immune regulation, and a breakdown in any of these layers can allow immune-mediated damage. What unites these diverse conditions is the eye’s fundamental vulnerability: a structure that evolved to be transparent, precisely organized, and exquisitely sensitive cannot tolerate the blunt-force collateral damage of an unchecked immune response, regardless of what originally triggered it.